McNeil's Haldol
Executive Summary
Company submits additional comments March 27 to a petition seeking five-year marketing exclusivity for Haldol (haloperidol decanoate) under the Patent Term Restoration Act. Citing a recent federal court decision involving Glaxo and the Patent Office, McNeil asserts that the ruling "supports the position that the term 'active moiety' cannot be used as equivalent to 'active ingredient' as defined in the Act." The company says that the product qualifies for exclusivity because haloperidol decanoate is the "active ingredient" of Haldol even though the drug is converted in vivo into haloperidol, an already approved drug.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.